Publication | Closed Access

Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA

Pediatric HematologyMedicinePathogenesisHematologyHistopathologyPathologyImmunologyCell-free Circulating DnaPediatric LangerhansBlood CellInborn Error Of ImmunityMolecular PathologyImmunotherapyMolecular DiagnosticsBraf V600e Mutation